2.5 mg clinical trials

A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)

This study looks at a new medicine called RTA 408 (also known as Skyclarys) for people with Friedreich's ataxia. It aims to see if the medicine is safe, how well it works to improve symptoms, and how it affects the body.